One To Watch

Alto Neuroscience

A Nasdaq-listed clinical-stage biotechnology company developing precision medicines for neuropsychiatric disorders. Alto Neuroscience focuses on biomarker-driven drug development designed to match patients with therapies most likely to be effective.

Company Overview

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through a precision medicine approach. Its strategy centers on integrating neurobiology, biomarkers and clinical data to develop targeted therapies for mental health disorders.

The company’s Precision Psychiatry Platform™ uses data such as EEG activity, cognitive testing, wearable signals and other biomarkers to identify patient subgroups more likely to respond to specific treatments.

This approach aims to address a core limitation in psychiatry: heterogeneous patient populations and variable drug response. Alto’s model is to pair drug development with patient stratification, improving clinical trial success rates and therapeutic outcomes.

Headquarters and Global Presence

headquartered in Mountain View, California, United States
conducts clinical trials globally through research partners and clinical sites

The company operates with a U.S.-centric footprint while advancing multinational clinical programs in neuropsychiatric disorders.

Founding and History

founded in 2019 by Amit Etkin, MD, PhD
went public on Nasdaq (ticker: ANRO)

The company was established to translate advances in neuroscience and biomarker research into clinical drug development. Its model reflects a broader shift toward precision medicine in psychiatry, analogous to oncology.

Alto has expanded its pipeline through internal development and acquisitions, including programs targeting treatment-resistant depression and other psychiatric conditions.

Therapy Areas and Focus

Alto Neuroscience focuses on neuropsychiatric disorders.

Key areas of development include:

major depressive disorder
bipolar depression
schizophrenia, including cognitive impairment
treatment-resistant depression
additional central nervous system disorders

The company prioritizes conditions with high unmet need and limited effective treatment options.

Technology Platforms and Modalities

The company’s platform integrates biomarker science with drug development.

Key components include:

Precision Psychiatry Platform™ combining EEG, cognitive, behavioral and wearable data
biomarker-driven patient stratification for clinical trials
AI-enabled analytics to match patients with therapies
small-molecule drug development targeting specific neural pathways

This approach is designed to improve both clinical trial efficiency and therapeutic efficacy by identifying responsive patient populations early.

Key Pipeline and Programs

ALTO-100 (amdiglurax)

Modality: oral small molecule promoting neuroplasticity
Indication focus: major depressive disorder and bipolar depression
Status: Phase IIb clinical development
Mechanism: enhances hippocampal neuroplasticity linked to mood and cognition

ALTO-101

Modality: PDE4 inhibitor (transdermal formulation)
Indication focus: schizophrenia with cognitive impairment
Status: Phase II clinical development
Mechanism: enhances intracellular signaling associated with cognition

ALTO-207

Modality: fixed-dose combination (dopamine agonist + 5-HT3 antagonist)
Indication focus: treatment-resistant depression
Status: advancing toward Phase IIb / later-stage development
Mechanism: enhances dopaminergic signaling while improving tolerability

Additional programs

ALTO-203: H3 receptor inverse agonist targeting cognition and wakefulness
ALTO-300: agomelatine-based therapy for depression
multiple Phase II programs using biomarker-driven patient selection

Key Personnel

Amit Etkin, Founder and Chief Executive Officer

The leadership team includes experts in psychiatry, neuroscience, biomarker research and clinical drug development.

Strategic Partnerships

Alto Neuroscience operates with a combination of internal development and external collaborations.

Key elements include:

clinical research partnerships supporting global trials
investor backing supporting precision psychiatry platform development
collaborations focused on biomarker discovery and validation

The company’s model emphasizes integration of clinical data and neuroscience research rather than reliance on large pharmaceutical partnerships.

FAQ Section

The central strategic issue is whether precision psychiatry can materially improve drug development success and clinical outcomes. The company must demonstrate that biomarker-driven patient selection leads to more effective therapies and higher trial success rates.

Psychiatric disorders are biologically heterogeneous, and patients often respond differently to the same treatment. Precision psychiatry aims to match therapies to patients based on measurable biological characteristics.

The company integrates biomarker identification directly into drug development. Its platform uses EEG, cognitive data and other signals to define patient subgroups most likely to benefit from specific therapies.

ALTO-100 is a lead program targeting neuroplasticity, a core mechanism implicated in depression. It serves as a key test of the company’s biomarker-driven approach to identifying responsive patients.

Alto focuses on neuropsychiatric conditions.

Key areas include:

major depressive disorder
bipolar depression
schizophrenia and cognitive impairment
treatment-resistant depression

Alto combines small-molecule drug development with biomarker-guided clinical trial design, aiming to identify responders early and improve efficacy signals in trials.

Key issues include: